Vaccine Development

FDA Approves Moderna’s mFlusiva for Adults 50 and Older

The authorization brings the first U.S.‑licensed mRNA seasonal flu vaccine but its public rollout is uncertain because the CDC advisory panel cannot meet to set formal recommendations.